Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) Enterprise Value (2023 - 2025)

Compass Therapeutics' Enterprise Value history spans 3 years, with the latest figure at -$208.9 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 64.12% year-over-year to -$208.9 million; the TTM value through Dec 2025 reached -$208.9 million, down 64.12%, while the annual FY2025 figure was -$208.9 million, 64.12% down from the prior year.
  • Enterprise Value for Q4 2025 was -$208.9 million at Compass Therapeutics, up from -$219.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$101.5 million in Q2 2025 and bottomed at -$219.9 million in Q3 2025.
  • The 3-year median for Enterprise Value is -$158.1 million (2023), against an average of -$157.4 million.
  • The largest YoY upside for Enterprise Value was 35.7% in 2025 against a maximum downside of 64.12% in 2025.
  • A 3-year view of Enterprise Value shows it stood at -$152.5 million in 2023, then increased by 16.51% to -$127.3 million in 2024, then crashed by 64.12% to -$208.9 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Enterprise Value are -$208.9 million (Q4 2025), -$219.9 million (Q3 2025), and -$101.5 million (Q2 2025).